Course Notes & other materials

Home
Week 1: 29 Aug
Week 2: 5 Sept
Week 3: 12 Sept
Week 4: 19 Sept
Week 5: 26 Sept
Week 6: 3 Oct
Week 7: 10 Oct
Week 8: 17 Oct
Week 9: 24 Oct
Week 10: 31 Oct
Week 11: 7 Nov
Week 12: 14 Nov
Week 13: 21 Nov
Week 14: 28 Nov

News & information

Unit 23 updated, 2017
Unit 24 updated, 2017

We'll be in Ed2 N 2301.


January 2018: Celgene (New Jersey) is taking over Juno Therapeutics, the other leading CAR-T startup, for $9 billion (it already owned 10% of the company, so the price is the same as Novartis paid for Kite.) The backstory is different: Juno's been having trouble with CAR-T toxicity, and Celgene is said to be running out of creative and business gas.

October 2017: Angry reaction to Novartis' price rumor has lowered the price to about $475,000.

September 2017: Amgen has made a deal with a Chinese company to market 4 biosimilar mAbs there. These were not originally invented by Amgen. One is probably a Humira copy; it's the world's largest-selling drug.

August 2017: In response to the news from Novartis (below) Gilead is about to buy Kite Pharma, which has a nearly-ready CAR-T, for $11 billion.

August 2017: Rumor has it that the first likely to be approved CAR-T therapy, from Novartis, will be priced at $649,000.

>
WEEK 12: 15 November

Unit 23: Tumor Immunology (PDF)

Supplemental material: If you have an interest in cancer research, the 2012 updated version of a classic paper is required reading: Hallmarks of Cancer: The Next Generation, by Douglas Hanahan and Robert Weinberg.

Unit 24: Immunomodulators and Biological Response Modifiers (PDF)

McGill's Cancer Center Rocks!